Pregnancy and epilepsy: scientists track how a key drug moves through the body
NCT ID NCT04117425
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study looks at how the epilepsy drug levetiracetam is processed in pregnant women and how much reaches the baby. Researchers will collect blood and saliva samples throughout pregnancy and at delivery, plus cord blood and amniotic fluid. The goal is to create a model that could one day help doctors personalize doses to keep both mother and baby safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- levetiracetam
- What this could lead to
- If successful, this could help doctors adjust levetiracetam doses during pregnancy to keep seizure control stable while minimizing risks.
- What could go wrong
- This is a small observational study (14 participants) focused on measuring drug levels, not testing a new treatment. Results may not apply to all pregnant women with epilepsy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY IN PREGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
hospital Cochin
Paris, 75014, France